Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

Sponsor
Beijing Friendship Hospital
Study ID
NCT04338438
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a single-arm, interventional study aimed to observe the efficacy and safety of Apatinib combined with S-1 for patients with advanced gastric cancer refractory to oxaliplatin plus capecitabine combination therapy

Key Dates

Start date
May 1, 2015
Status verified
Nov 2020
Primary completion
Apr 30, 2019
Completion
Jan 31, 2020

Study Design

Enrollment
37 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib Mesylate tablets combined with S-1 capsules
    single arm trial: apatinib 500 mg once daily, across entire cycle and S-1 60 mg twice daily, on the first 14 days of a 21-day cycle. Medication was continued until the disease progression, withdrawal requirement, or intolerable adverse events

Primary Outcome Measure

median progression-free survival(mPFS) [ Time Frame: 2 years ]

Related Studies